Shares of GSK PLC GSK rose 1.40% to £14.80 Monday, on what proved to be an all-around favorable trading session for the stock ...

Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus ...

Today, a brief rundown of news from GSK and Roivant, as well as updates from Zealand Pharma, Eli Lilly and Xencor that you may have missed. GSK will not advance an experimental vaccine for the herpes ...

Next up is pharmaceutical giant GSK (LSE: GSK). Like ITV, the stock’s struggled over the last five years. During that time, it’s lost 7.9% of its value. However, it’s started to reverse its ...

Former head chef at The Apollo Stefano Marano (right) and business partner Jack Reid will open Avia, a 60-seat European restaurant, near Taylor Square.Traianos Pakioufakis In May, Big Poppa’s ...

The company has a new logo, designed by Pentagram, that looks incredibly plain — especially compared to previous iterations of the logo that featured a rakish slant, two shades of blue ...

This summer, GSK cut its yearly vaccine sales projection on the back of a narrowed recommendation for adult respiratory syncytial virus (RSV) vaccines from the Centers for Disease Control and ...

GSK has demonstrated robust sales growth, with a 13% increase to GBP 7.9 billion and a core operating profit up by 21% to GBP 2.5 billion, as noted by CEO Emma Walmsley in the latest earnings call.

Credit: CeltStudio/Shutterstock. Japan’s Ministry of Health, Labour and Welfare (MHLW) has accepted for review GSK‘s new drug application (NDA) for Blenrep (belantamab mafodotin) to treat patients ...

GSK has turned to Brooke Shields to get the message out about shingles vaccination. The drugmaker has worked with the model and actor to talk to female celebrities and patients aged 50 years and ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.50. The company’s shares opened today at p1,644. ...

An analysis of data from the phase 2 portion of the trial showed the primary efficacy objective had not been met. A study investigating GSK’s investigational herpes simplex virus (HSV) vaccine ...